PeptideDB

L-371,257 162042-44-6

L-371,257 162042-44-6

CAS No.: 162042-44-6

L-371,257 (L371,257) is a novel and potent non-peptide oxytocin (OT) receptor antagonist (pA2=8.4). It exhibits high aff
Data collection:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

L-371,257 (L371,257) is a novel and potent non-peptide oxytocin (OT) receptor antagonist (pA2=8.4). It exhibits high affinity against oxytocin receptor (Ki=19 nM) and vasopressin V1a receptor (Ki=3.7 nM).



Physicochemical Properties


Molecular Formula C28H33N3O6
Molecular Weight 507.59
Exact Mass 507.237
Elemental Analysis C, 66.26; H, 6.55; N, 8.28; O, 18.91
CAS # 162042-44-6
PubChem CID 6918320
Appearance White to off-white solid powder
LogP 3.787
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 6
Rotatable Bond Count 5
Heavy Atom Count 37
Complexity 823
Defined Atom Stereocenter Count 0
SMILES

CC(=O)N1CCC(CC1)OC2=CC(=C(C=C2)C(=O)N3CCC(CC3)N4C5=CC=CC=C5COC4=O)OC

Synonyms

L371,257 L 371,257 L-371,257
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vivo Body weight growth is stimulated by systemic injection of the non-osmotic oxytocin receptor antagonist L-371,257 (0.5 and 1.0 mg/kg; i.p.) [3].
Animal Protocol Animal/Disease Models: Six-hour fasted rats [3]
Doses: 0.5 and 1.0 mg/kg
Route of Administration: intraperitoneal (ip) injection (single) at the beginning of the dark cycle and 30-45 minutes before eating; intraperitoneal (ip) injection (repeated injection) for 6 days.
Experimental Results: Single injections of 0.5 and 1.0 mg/kg Dramatically stimulated weight gain relative to vehicle treatment. When repeated over 6 days, 0.5 mg/kg Dramatically stimulated body weight gain (10.5±2.2 g) relative to vehicle treatment (4.7±2.7 g).
References

[1]. 1-(1-[4-[(N-acetyl-4-piperidinyl)oxy]-2-methoxybenzoyl]piperidin-4- yl)-4H-3,1-benzoxazin-2(1H)-one (L-371,257): a new, orally bioavailable, non-peptide oxytocin antagonist. J Med Chem. 1995 Nov 10;38(23):4634-6.

[2]. Oxytocin blocks enhanced motivation for alcohol in alcohol dependence and blocks alcohol effects on GABAergic transmission in the central amygdala. PLoS Biol. 2019 Apr 16;17(4):e2006421.

[3]. Hindbrain oxytocin receptors contribute to the effects of circulating oxytocin on food intake in male rats. Endocrinology. 2014 Aug;155(8):2845-57.


Solubility Data


Solubility (In Vitro) DMSO : ~8.33 mg/mL (~16.41 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 0.83 mg/mL (1.64 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: ≥ 0.83 mg/mL (1.64 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 3: ≥ 0.83 mg/mL (1.64 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 1.9701 mL 9.8505 mL 19.7009 mL
5 mM 0.3940 mL 1.9701 mL 3.9402 mL
10 mM 0.1970 mL 0.9850 mL 1.9701 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.